Oncology

Latest News

Patients in the cemiplimab group had superior disease-free survival vs placebo. | Image credit: Medical Works - stock.adobe.com
Cemiplimab Improves Disease-Free Survival in High-Risk, Advanced CSCC

June 13th 2025

Cemiplimab improved disease-free survival in patients with high-risk cutaneous squamous cell carcinoma (CSCC) and performed well in patients with advanced CSCC in the real-world setting.

The approval covers use of pembrolizumab as a single agent in the neoadjuvant setting, followed by adjuvant treatment with pembrolizumab in combination with radiotherapy with or without cisplatin after surgery, and then continued as a single agent. | Image credit: wladimir1804-stock.adobe.com
FDA Approves Perioperative Pembrolizumab in Resectable HNSCC

June 13th 2025

FDA approval-Olivier Le Moal-stock.adobe.com.jpeg
Mitomycin Intravesical Solution Gains FDA Approval for Recurrent Low-Grade NMIBC

June 12th 2025

AJMC
Utilization and Costs Among Oncologists Participating in a Private Insurance Shared Savings Model

June 11th 2025

The new report suggests the C5a-C5aRq axis might be a useful target in combination with existing therapies for cutaneous squamous cell carcinoma. | Image credit: vladimircaribb - stock.adobe.com
C5aR1 Flagged as Biomarker in Cutaneous Squamous Cell Carcinoma

June 7th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Dr Leonard Fromer Discusses Precision Medicine in Oncology
November 30th 2016

Dr Leonard Fromer Discusses Precision Medicine in Oncology

Cancer patients can now receive individually personalized treatment thanks to algorithms that account for their own unique factors, according to Leonard M. Fromer, MD, FAAFP, executive medical director of the Group Practice Forum.
Site Logo
November 29th 2016

Hospitalization a Major Burden on Medicare Beneficiaries With Cancer

Surabhi Dangi-Garimella, PhD
A nationally representative study among patients enrolled in Medicare, who were diagnosed with cancer, found that out-of-pocket costs averaged at 23.7% of their household income. A majority of these costs could be attributed to hospitalization.
Site Logo
November 29th 2016

ASCO Framework Can Help Providers Assess Clinical Pathway Programs

Surabhi Dangi-Garimella, PhD
The American Society of Clinical Oncology (ASCO) has released the Criteria for High-Quality Clinical Pathways in Oncology, which is expected to help providers assess the quality, utility, and integrity of pathway programs in the United States.
Site Logo
November 29th 2016

What We're Reading: Warren Says Pharma "Hijacked" Cures Bill

AJMC Staff
What we're reading, November 29, 2016: Warren cries foul over pharma's role in legislation; women fear what will happen to coverage under Trump; and Gallup poll finds most Americans want changes or repeal of the Affordable Care Act.
Site Logo
November 28th 2016

21st Century Cures Set for a Midweek House Vote

Surabhi Dangi-Garimella, PhD
With $372 million carved out for the National Institutes of Health innovation account in 2017, and about $114 million assigned to President Barack Obama’s Precision Medicine Initiative for the fiscal year 2018, the 21st Century Cures Act has a lot at stake for healthcare in the United States.
Kim Eason Explains Horizon's Use of Bundled Payment Model for Oncology
November 26th 2016

Kim Eason Explains Horizon's Use of Bundled Payment Model for Oncology

Oncology is a perfect fit for the bundled payment model, because it evaluates the outcomes, patient satisfaction, and cost of an oncology episode, said Kim Eason, manager at Horizon Blue Cross Blue Shield of NJ. She said that Horizon adopted the bundled payment model early to cope with New Jersey’s rising healthcare costs.
Site Logo
November 26th 2016

Mitigating Chemotherapy-Induced Neutropenia With a Novel Same-Day Treatment

AJMC Staff
Trial data on the use of plinabulin for mitigating chemotherapy-induced neutropenia with docetaxel will be presented as a poster at the American Society of Hematology’s annual meeting in San Diego.
Site Logo
November 25th 2016

Risk Factors for Neutropenia and Infections in Childhood ALL

AJMC Staff
A study published in the Annals of Oncology has analyzed data on young patients with acute lymphoblastic leukemia (ALL) to evaluate risk factors for febrile neutropenia and infection-related complications.
The Future of Value-Based Care and Payment Models in Cancer Care
November 24th 2016

The Future of Value-Based Care and Payment Models in Cancer Care

Do APMs Incorporate Survivorship Care in Oncology?
November 24th 2016

Do APMs Incorporate Survivorship Care in Oncology?

Patient Centricity of Care Delivery and Payment Models
November 24th 2016

Patient Centricity of Care Delivery and Payment Models

The Balancing Act of Healthcare Costs
November 24th 2016

The Balancing Act of Healthcare Costs

Innovative Technology and Healthcare Costs
November 24th 2016

Innovative Technology and Healthcare Costs

Importance of Data Sharing in Healthcare
November 24th 2016

Importance of Data Sharing in Healthcare

Leveraging Health IT in Cancer Care
November 24th 2016

Leveraging Health IT in Cancer Care

Who Shares the Maximum Risk With Innovative Treatments in Oncology?
November 24th 2016

Who Shares the Maximum Risk With Innovative Treatments in Oncology?

Site of Service and the Challenge of Value-Based Care
November 24th 2016

Site of Service and the Challenge of Value-Based Care

Risk-Based Contracting in Oncology
November 24th 2016

Risk-Based Contracting in Oncology

Benefits of a Medical Home Model in Oncology
November 24th 2016

Benefits of a Medical Home Model in Oncology

Population Health and APMs
November 24th 2016

Population Health and APMs

Is the Oncology Care Model Patient Centered?
November 24th 2016

Is the Oncology Care Model Patient Centered?

Value-Based Care and APMs in Oncology: A Payer Perspective
November 24th 2016

Value-Based Care and APMs in Oncology: A Payer Perspective

Adapting and Paying for Value-Based Care
November 24th 2016

Adapting and Paying for Value-Based Care

Defining Alternative Payment Models
November 24th 2016

Defining Alternative Payment Models

Site Logo
November 23rd 2016

Another Death Reported in Juno's CAR-T Trial in Patients With ALL

AJMC Staff
Within 4 months of the last reported incident, Juno Therapeutics has again halted the phase 2 “Rocket” trial of JCAR015 in patients with relapsed or refractory B cell acute lymphoblastic leukemia (ALL).
Site Logo
November 23rd 2016

5 Key Highlights From the Patient-Centered Oncology Care Meeting

Surabhi Dangi-Garimella, PhD
Here's a glimpse into what The American Journal of Managed Care’s 5th annual Patient-Centered Oncology Care® meeting had in store for its attendees.
Dr Robert Carlson Predicts 2017 Will Be "Year of Uncertainty" For Healthcare
November 23rd 2016

Dr Robert Carlson Predicts 2017 Will Be "Year of Uncertainty" For Healthcare

There is significant uncertainty surrounding the healthcare system’s future in 2017 under a Republican Congress and President, but it’s unlikely that the Affordable Care Act will be repealed without some replacement that accommodates the individuals newly covered by it, said Robert W. Carlson, MD, CEO of the National Comprehensive Cancer Network.
PCOC16: Panel Discussion on the Future of Oncology Care
November 23rd 2016

PCOC16: Panel Discussion on the Future of Oncology Care

The 5th Annual Patient-Centered Oncology Care Meeting closed out with a panel discussion with an eye on the future. Donald Trump's surprise election has caused turmoil in the healthcare industry as the Affordable Care Act seems certain to be repealed at least in part. However, the move to value-based care will likely continue as planned.
This Week in Managed Care: November 23, 2016
November 23rd 2016

This Week in Managed Care: November 23, 2016

This week, the top managed care stories included the FDA's approval of rival combination therapies for type 2 diabetes, the American Medical Association issued mHealth guidelines, and a study found the dementia rate declining.
Debra Madden: Oncologists Should Anticipate Patient Concerns About Immunotherapy
November 23rd 2016

Debra Madden: Oncologists Should Anticipate Patient Concerns About Immunotherapy

When helping cancer patients decide if immuno-oncology treatments are right for them, clinicians should not focus only on the potential risks and benefits, said Debra L. Madden, cancer research advocate and patient representative. Oncologists should ensure patients are aware of the variable responses to the therapy, like the phenomenon of pseudoprogression.
<1
...
878889909192939495
...
186>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo